Merck announced that Belsomra (suvorexant) tablets are now available for the treatment of insomnia in adults who have difficulty falling asleep and/or staying asleep. Belsomra has been scheduled as a CIV controlled substance due to its abuse and dependence potential.
Belsomra is the first orexin receptor antagonist approved for the treatment of insomnia. The mechanism by which it exerts its therapeutic effect in insomnia is presumed to be through antagonism of orexin receptors. Blocking the binding of wake-promoting neuropeptides orexin A and orexin B to receptors OX1R and OX2R is thought to suppress wake drive.
Belsomra is available in 5mg, 10mg, 15mg, and 20mg strength tablets in 30-count blisters.
For more information call (877) 888-4231 or visit Belsomra.com.